Cargando…
Effect of phosphodiesterase inhibitors in the bladder
Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-channel modulated pathways, and the l-cystei...
Autores principales: | Chughtai, Bilal, Ali, Aizaz, Dunphy, Claire, Kaplan, Steven A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730687/ https://www.ncbi.nlm.nih.gov/pubmed/29264117 http://dx.doi.org/10.1016/j.ajur.2015.04.014 |
Ejemplares similares
-
Contemporary review of the 532 nm laser for treatment of benign prostatic hyperplasia
por: Chughtai, Bilal, et al.
Publicado: (2015) -
Rationale for the Use of Prostaglandins and Phosphodiesterase Inhibitors in the Treatment of Functional Bladder Disorders
por: Rahnama'i, Mohammad Sajjad, et al.
Publicado: (2013) -
Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019) -
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020) -
Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)